Imagine lifesaving vascular access or replacement of segments of a patient’s blood vessels without requiring any cells or tissue from the patient.
At Humacyte, this vision may become a reality thanks to our proprietary technology and process for developing HAV products that are currently being investigated in the clinic.
The failure rate for current plastic dialysis grafts is high, with complications that include infection, thrombosis, and neo-intimal hyperplasia. Investigational HAVs are found to be more resistant to these failure modes in initial investigational trials.
Using investigational HAVs means that other surrogate blood vessels, e.g., saphenous vein from the leg, won’t have to be removed from the
patient. This approach saves the patient’s vein and the patient from additional operations.
Investigational HAVs have the potential to be grown, stored and immediately available for vascular access or as a peripheral graft throughout the body.
Surgical creation of vascular accesses may be costly, and complications often arise. The more durable investigational HAVs have
the potential to avoid complications and more surgeries, yielding potential significant health care cost savings.
More than 465,000 people in the
U.S. with End-Stage Renal Disease
(ESRD) undergo hemodialysis
Current vascular access options
have poor durability or functional
patency, and ultimately fail.
investigational HAVs) could serve as
a potential alternative to synthetic
fluoropolymers (plastic grafts)
in these patients.
In clinical trials, HUMACYL® has
shown the potential to resist
inflammatory and immune
responses from the recipient. These
attributes make HUMACYL® a great
alternative and confer potential
remarkable advantages vs. other
potentially competing and largely